Simeon George
CIK 1595117 · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$98.21M
Companies
11
Total Filings
48
Lifetime Open-Market Net
$406.11M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NKTX | Director | 666,667 | $2.86 | $1.91M | $40.00M | 9 | 2026-06-11 |
| DSGN | Director | 6,486,476 | $10.97 | $71.16M | $12.57M | 8 | 2026-06-11 |
| CRSP | Director | 238,897 | $49.80 | $11.90M | $51.50M | 11 | 2026-06-09 |
| ODTX | 10%+ Owner | 734,868 | — | — | $19.94M | 1 | 2026-05-11 |
| AVLN | 10%+ Owner | 1,419,298 | — | — | $20.00M | 1 | 2026-05-01 |
| ZBIO | 10%+ Owner | 669,061 | $19.80 | $13.25M | $76.00M | 1 | 2024-09-16 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 0 | $76.01 | $0 | $18.85M | 6 | 2022-08-17 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 2,216,960 | $115.07 | $255.11M | $150.00M | 1 | 2022-02-10 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | 0 | — | — | $14.59M | 6 | 2020-09-28 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 3,220,627 | — | — | $931.0K | 3 | 2017-06-02 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 919,467 | $0.00 | $552 | $1.73M | 1 | 2014-02-11 |
Recent Filings · Page 2 of 5
48 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-17 | DSGN | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | NKTX | Grant (A) | — | $0 | EDGAR |
| 2024-05-31 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2024-03-28 | NKTX | Buy (P) | +2,000,000 | $20.00M | EDGAR |
| 2024-02-27 | CRSP | Grant (A) | +1,048,951 | $75.00M | EDGAR |
| 2023-06-09 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | NKTX | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | DSGN | Grant (A) | — | $0 | EDGAR |
| 2022-12-20 | DSGN | Buy (P) | +900,000 | $7.57M | EDGAR |
| 2022-08-17 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Disp (D) | −2,253,660 | -$171.28M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.